JP2015523326A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015523326A5 JP2015523326A5 JP2015510839A JP2015510839A JP2015523326A5 JP 2015523326 A5 JP2015523326 A5 JP 2015523326A5 JP 2015510839 A JP2015510839 A JP 2015510839A JP 2015510839 A JP2015510839 A JP 2015510839A JP 2015523326 A5 JP2015523326 A5 JP 2015523326A5
- Authority
- JP
- Japan
- Prior art keywords
- moiety
- tissue targeting
- complex according
- targeting moiety
- complex
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 230000008685 targeting Effects 0.000 claims 15
- 238000000034 method Methods 0.000 claims 8
- 239000003446 ligand Substances 0.000 claims 7
- 230000008878 coupling Effects 0.000 claims 6
- 238000010168 coupling process Methods 0.000 claims 6
- 238000005859 coupling reaction Methods 0.000 claims 6
- 239000007864 aqueous solution Substances 0.000 claims 5
- SNUSZUYTMHKCPM-UHFFFAOYSA-N 1-hydroxypyridin-2-one Chemical compound ON1C=CC=CC1=O SNUSZUYTMHKCPM-UHFFFAOYSA-N 0.000 claims 4
- ZSLUVFAKFWKJRC-IGMARMGPSA-N 232Th Chemical compound [232Th] ZSLUVFAKFWKJRC-IGMARMGPSA-N 0.000 claims 4
- 229910052776 Thorium Inorganic materials 0.000 claims 4
- 125000002768 hydroxyalkyl group Chemical group 0.000 claims 4
- GQZXNSPRSGFJLY-UHFFFAOYSA-N hydroxyphosphanone Chemical group OP=O GQZXNSPRSGFJLY-UHFFFAOYSA-N 0.000 claims 4
- 150000002500 ions Chemical class 0.000 claims 4
- 230000002285 radioactive effect Effects 0.000 claims 4
- 101000934338 Homo sapiens Myeloid cell surface antigen CD33 Proteins 0.000 claims 3
- 102100025243 Myeloid cell surface antigen CD33 Human genes 0.000 claims 3
- 206010028980 Neoplasm Diseases 0.000 claims 3
- 239000003153 chemical reaction reagent Substances 0.000 claims 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 3
- 239000012634 fragment Substances 0.000 claims 3
- 125000005647 linker group Chemical group 0.000 claims 3
- 230000003381 solubilizing effect Effects 0.000 claims 3
- 201000009030 Carcinoma Diseases 0.000 claims 2
- 206010025323 Lymphomas Diseases 0.000 claims 2
- 206010035226 Plasma cell myeloma Diseases 0.000 claims 2
- 206010039491 Sarcoma Diseases 0.000 claims 2
- 201000011510 cancer Diseases 0.000 claims 2
- 201000010099 disease Diseases 0.000 claims 2
- 206010020718 hyperplasia Diseases 0.000 claims 2
- 230000002390 hyperplastic effect Effects 0.000 claims 2
- 208000032839 leukemia Diseases 0.000 claims 2
- 201000000050 myeloid neoplasm Diseases 0.000 claims 2
- BUXKULRFRATXSI-UHFFFAOYSA-N 1-hydroxypyrrole-2,5-dione Chemical compound ON1C(=O)C=CC1=O BUXKULRFRATXSI-UHFFFAOYSA-N 0.000 claims 1
- 108010021625 Immunoglobulin Fragments Proteins 0.000 claims 1
- 102000008394 Immunoglobulin Fragments Human genes 0.000 claims 1
- 150000001408 amides Chemical class 0.000 claims 1
- 125000005604 azodicarboxylate group Chemical group 0.000 claims 1
- 150000001718 carbodiimides Chemical class 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 125000004185 ester group Chemical group 0.000 claims 1
- RTZKZFJDLAIYFH-UHFFFAOYSA-N ether Substances CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims 1
- 125000001183 hydrocarbyl group Chemical group 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 230000001613 neoplastic effect Effects 0.000 claims 1
- 239000003960 organic solvent Substances 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 108090000765 processed proteins & peptides Proteins 0.000 claims 1
- 125000001424 substituent group Chemical group 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB201208309A GB201208309D0 (en) | 2012-05-11 | 2012-05-11 | Complexes |
| GB1208309.3 | 2012-05-11 | ||
| PCT/EP2013/059840 WO2013167755A1 (en) | 2012-05-11 | 2013-05-13 | Radio-pharmaceutical complexes |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2015523326A JP2015523326A (ja) | 2015-08-13 |
| JP2015523326A5 true JP2015523326A5 (OSRAM) | 2016-06-16 |
Family
ID=46458687
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015510840A Expired - Fee Related JP6219372B2 (ja) | 2012-05-11 | 2013-05-13 | 放射性医薬錯体 |
| JP2015510838A Expired - Fee Related JP6211066B2 (ja) | 2012-05-11 | 2013-05-13 | 放射性医薬錯体 |
| JP2015510839A Pending JP2015523326A (ja) | 2012-05-11 | 2013-05-13 | 放射性医薬錯体 |
Family Applications Before (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015510840A Expired - Fee Related JP6219372B2 (ja) | 2012-05-11 | 2013-05-13 | 放射性医薬錯体 |
| JP2015510838A Expired - Fee Related JP6211066B2 (ja) | 2012-05-11 | 2013-05-13 | 放射性医薬錯体 |
Country Status (9)
| Country | Link |
|---|---|
| US (3) | US20150147272A1 (OSRAM) |
| EP (3) | EP2846843A1 (OSRAM) |
| JP (3) | JP6219372B2 (OSRAM) |
| KR (3) | KR20150092701A (OSRAM) |
| CN (3) | CN104602716A (OSRAM) |
| CA (3) | CA2873144C (OSRAM) |
| GB (1) | GB201208309D0 (OSRAM) |
| HK (3) | HK1206981A1 (OSRAM) |
| WO (3) | WO2013167754A1 (OSRAM) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2659251C (en) | 2006-07-10 | 2016-06-14 | The Regents Of The University Of California | Luminescent 1-hydroxy-2-pyridinone chelates of lanthanides |
| WO2011025790A1 (en) | 2009-08-24 | 2011-03-03 | Lumiphore, Inc. | Macrocyclic hopo chelators |
| GB201002508D0 (en) | 2010-02-12 | 2010-03-31 | Algeta As | Product |
| GB201208309D0 (en) | 2012-05-11 | 2012-06-27 | Algeta As | Complexes |
| US11453652B2 (en) | 2013-03-15 | 2022-09-27 | Lumiphore, Inc. | Di-macrocycles |
| MA41176A (fr) * | 2014-12-17 | 2017-10-24 | Bayer As | Complexes radio-pharmaceutiques |
| WO2017105565A2 (en) * | 2015-09-10 | 2017-06-22 | Memorial Sloan Kettering Cancer Center | Compositions for therapeutics, targeted pet imaging and methods of their use |
| GB201600158D0 (en) * | 2016-01-05 | 2016-02-17 | Bayer As | Purification method |
| GB201600154D0 (en) * | 2016-01-05 | 2016-02-17 | Bayer As | Isotope preparation method |
| SG10202009424TA (en) * | 2016-03-24 | 2020-11-27 | Bayer Pharma AG | Radio-pharmaceutical complexes |
| JP2019517547A (ja) | 2016-06-10 | 2019-06-24 | バイエル・ファルマ・アクティエンゲゼルシャフト | 放射性医薬品錯体 |
| CA3054248A1 (en) | 2017-02-24 | 2018-08-30 | Bayer As | Combination therapy comprising a radiopharmaceutical and a dna-repair inhibitor |
| CN111918877A (zh) * | 2018-03-14 | 2020-11-10 | 美国卫生和人力服务部 | 抗cd33嵌合抗原受体及其用途 |
| WO2020043617A1 (en) | 2018-08-28 | 2020-03-05 | Bayer As | Combination of pi3k-inhibitors and targeted thorium conjugates |
| WO2020106886A1 (en) * | 2018-11-20 | 2020-05-28 | Cornell University | Macrocyclic complexes of radionuclides and their use in radiotherapy of cancer |
| USD885822S1 (en) | 2018-12-14 | 2020-06-02 | Whirlpool Corporation | Food grinder |
| CA3130747A1 (en) | 2019-02-21 | 2020-08-27 | Bayer Aktiengesellschaft | Combination of pd-1/pd-l1 inhibitors and targeted thorium conjugates |
| US20220118123A1 (en) | 2019-02-22 | 2022-04-21 | Bayer Aktiengesellschaft | Combination of ar antagonists and targeted thorium conjugates |
| AR119479A1 (es) | 2019-07-25 | 2021-12-22 | Bayer As | Radiofármacos dirigidos para diagnóstico y tratamiento de cáncer |
| CA3167409A1 (en) * | 2020-01-10 | 2021-07-15 | Fusion Pharmaceuticals Inc. | Macrocyclic chelates and uses thereof |
| CA3164710A1 (en) * | 2020-01-23 | 2021-07-29 | Saleem S. Drera | Systems and methods for preparing tailored radioactive isotope solutions |
| US20240000838A1 (en) * | 2020-11-30 | 2024-01-04 | Simcere Innovation, Inc. | Universal chimeric antigen receptor-expressing immune cells for allogeneic cell therapy |
| WO2022157094A2 (en) | 2021-01-22 | 2022-07-28 | Bayer Aktiengesellschaft | Lrrc15 antibodies and conjugates thereof |
| WO2025058000A1 (ja) | 2023-09-13 | 2025-03-20 | 東レ株式会社 | 癌の治療、予防及び／又は診断用医薬組成物 |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4698431A (en) * | 1985-11-12 | 1987-10-06 | The United States Of America As Represented By The United States Department Of Energy | Hydroxypyridonate chelating agents |
| US5624901A (en) | 1994-04-15 | 1997-04-29 | The Regents Of The University Of California | 3-hydroxy-2(1H)-pyridinone chelating agents |
| US8383081B2 (en) * | 1999-05-10 | 2013-02-26 | Immunomedics, Inc. | Anti-CD74 immunoconjugates and methods of use |
| NO312708B1 (no) | 2000-02-21 | 2002-06-24 | Anticancer Therapeutic Inv Sa | Radioaktive liposomer til terapi |
| NO313180B1 (no) | 2000-07-04 | 2002-08-26 | Anticancer Therapeutic Inv Sa | Bensökende alfapartikkel emitterende radiofarmasöytika |
| GB0308731D0 (en) | 2003-04-15 | 2003-05-21 | Anticancer Therapeutic Inv Sa | Method of radiotherapy |
| US7794691B2 (en) * | 2004-06-25 | 2010-09-14 | The European Community, Represented By The European Commission | Radionuclides for medical use |
| WO2006003123A2 (en) * | 2004-06-25 | 2006-01-12 | The European Community, Represented By The European Commission | Radionuclides for medical use |
| WO2008063721A2 (en) | 2006-08-15 | 2008-05-29 | The Regents Of The University Of California | Luminescent macrocyclic lanthanide complexes |
| EP2104662A2 (en) | 2007-01-11 | 2009-09-30 | GE Healthcare AS | Chelating agents |
| US9603954B2 (en) * | 2009-07-22 | 2017-03-28 | Actinium Pharmaceuticals Inc. | Methods for generating radioimmunoconjugates |
| EP2516407A4 (en) * | 2009-12-24 | 2013-06-12 | Lumiphore Inc | RADIOPHARMACEUTICAL COMPLEXES |
| EP2359802B1 (en) * | 2010-02-12 | 2014-06-18 | Evonik Degussa GmbH | Cosmetic composition containing polyglycerol partial ester |
| GB201002508D0 (en) | 2010-02-12 | 2010-03-31 | Algeta As | Product |
| GB201208309D0 (en) | 2012-05-11 | 2012-06-27 | Algeta As | Complexes |
-
2012
- 2012-05-11 GB GB201208309A patent/GB201208309D0/en not_active Ceased
-
2013
- 2013-05-13 JP JP2015510840A patent/JP6219372B2/ja not_active Expired - Fee Related
- 2013-05-13 WO PCT/EP2013/059839 patent/WO2013167754A1/en not_active Ceased
- 2013-05-13 WO PCT/EP2013/059841 patent/WO2013167756A1/en not_active Ceased
- 2013-05-13 WO PCT/EP2013/059840 patent/WO2013167755A1/en not_active Ceased
- 2013-05-13 JP JP2015510838A patent/JP6211066B2/ja not_active Expired - Fee Related
- 2013-05-13 KR KR1020147034742A patent/KR20150092701A/ko not_active Withdrawn
- 2013-05-13 CN CN201380035189.1A patent/CN104602716A/zh active Pending
- 2013-05-13 CA CA2873144A patent/CA2873144C/en not_active Expired - Fee Related
- 2013-05-13 CN CN201380036807.4A patent/CN104619355A/zh active Pending
- 2013-05-13 KR KR1020147034741A patent/KR20150092700A/ko not_active Withdrawn
- 2013-05-13 HK HK15107608.2A patent/HK1206981A1/xx unknown
- 2013-05-13 CN CN201380036905.8A patent/CN104540530A/zh active Pending
- 2013-05-13 EP EP13721975.4A patent/EP2846843A1/en not_active Withdrawn
- 2013-05-13 KR KR1020147034743A patent/KR20150092702A/ko not_active Withdrawn
- 2013-05-13 CA CA 2873143 patent/CA2873143A1/en not_active Abandoned
- 2013-05-13 US US14/400,031 patent/US20150147272A1/en not_active Abandoned
- 2013-05-13 US US14/400,020 patent/US20150104385A1/en not_active Abandoned
- 2013-05-13 JP JP2015510839A patent/JP2015523326A/ja active Pending
- 2013-05-13 HK HK15108017.5A patent/HK1207307A1/xx unknown
- 2013-05-13 EP EP13725586.5A patent/EP2846844B1/en active Active
- 2013-05-13 HK HK15107609.1A patent/HK1206982A1/xx unknown
- 2013-05-13 US US14/400,026 patent/US9827336B2/en not_active Expired - Fee Related
- 2013-05-13 EP EP13721784.0A patent/EP2846842A1/en not_active Withdrawn
- 2013-05-13 CA CA2873142A patent/CA2873142A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2015517482A5 (OSRAM) | ||
| Wang et al. | A review on curability of cancers: more efforts for novel therapeutic options are needed | |
| JP6211066B2 (ja) | 放射性医薬錯体 | |
| Maruani et al. | A plug-and-play approach to antibody-based therapeutics via a chemoselective dual click strategy | |
| Alewine et al. | Efficacy of RG7787, a next-generation mesothelin-targeted immunotoxin, against triple-negative breast and gastric cancers | |
| SI2533817T1 (en) | Target complexes that emit alpha particles containing thorium radionuclide and a ligand containing hydroxypyridinone | |
| JP7270596B2 (ja) | 抗ｄｏｔａ／抗腫瘍抗原二重特異性抗体による事前標的化放射免疫治療のためのｄｏｔａ－ハプテン組成物 | |
| RU2016150377A (ru) | Сайт-специфичная конъюгация линкерных лекарственных препаратов с антителами и получаемые в результате adc | |
| CN107250104B (zh) | 新型成像组合物及其用途 | |
| JP2010535713A5 (OSRAM) | ||
| Lee et al. | A PSMA-targeted bispecific antibody for prostate cancer driven by a small-molecule targeting ligand | |
| SI2894162T1 (en) | Identification of tumor-associated antigens for diagnosis and therapy | |
| RU2015140122A (ru) | Новые конъюгаты антител и их применения | |
| IL278574B2 (en) | Glycan-interacting compounds and methods of use | |
| JP2019527561A5 (OSRAM) | ||
| RU2019111303A (ru) | Антитела против edb и конъюгаты антитело-лекарственное средство | |
| RU2016116549A (ru) | Антитела против epcam и способы их применения | |
| JP7836270B2 (ja) | 抗ｄｏｔａ／抗腫瘍抗原二重特異性抗体による事前標的化放射免疫治療のためのｄｏｔａ－ハプテン組成物 | |
| JP2018506513A (ja) | 放射性医薬錯体 | |
| IL308504A (en) | Anti-ror2 antibodies, antibody fragments, their immunoconjugates and uses thereof | |
| Surendra Panikar et al. | PET and optical imaging of caveolin-1 in gastric tumors | |
| JP2016540826A5 (OSRAM) | ||
| US20070297983A1 (en) | Inhibition of breast carcinoma stem cell growth and metastasis | |
| Nie et al. | Small-Cell Lung Cancer Updates | |
| Feng et al. | Preclinical Development and Comparison of [99mTc] Tc/[177Lu] Lu-Labeled Anti-Trop2 Fc-Fused Nanobodies as Pancreatic Cancer Theranostics |